Rituximab removes intrarenal B cell clusters in patients with renal vascular allograft rejection.
Standard
Rituximab removes intrarenal B cell clusters in patients with renal vascular allograft rejection. / Steinmetz, Oliver; Lange-Hüsken, Felix; Turner, Jan Eric; Vernauer, Almut; Helmchen, Udo; Stahl, Rolf A.K.; Thaiss, Friedrich; Panzer, Ulf.
In: TRANSPLANTATION, Vol. 84, No. 7, 7, 2007, p. 842-850.Research output: SCORING: Contribution to journal › SCORING: Journal article › Research › peer-review
Harvard
APA
Vancouver
Bibtex
}
RIS
TY - JOUR
T1 - Rituximab removes intrarenal B cell clusters in patients with renal vascular allograft rejection.
AU - Steinmetz, Oliver
AU - Lange-Hüsken, Felix
AU - Turner, Jan Eric
AU - Vernauer, Almut
AU - Helmchen, Udo
AU - Stahl, Rolf A.K.
AU - Thaiss, Friedrich
AU - Panzer, Ulf
PY - 2007
Y1 - 2007
N2 - BACKGROUND: Intrarenal B cell clusters are associated with poor clinical outcome in acute interstitial rejection. The incidence of B cell aggregates in vascular rejection and the effect of therapy with the monoclonal CD20 antibody rituximab on intrarenal B cells are currently unclear. METHODS: We analyzed the incidence of B cell clusters in patients with vascular rejection by immunohistochemistry and compared the influence of rituximab treatment plus conventional therapy with that of conventional immunosuppression alone on intrarenal B cells. Furthermore intrarenal expression of the B cell attracting chemokine BCA-1/CXCL13 and the lymphoid chemokine SLC/CCL21 were analyzed. RESULTS: Nine of 16 patients with vascular rejection displayed intrarenal B cell clusters strictly co-localizing with expression of the B cell attractant chemokine BCA-1/CXCL13. Addition of rituximab to conventional treatment lead to complete depletion of intrarenal B cells (98.3+/-136.4 CD20, 90.7+/-113.2 CD19 vs. 0+/-0 CD20, 0+/-0 CD19 B cells/hpf, P
AB - BACKGROUND: Intrarenal B cell clusters are associated with poor clinical outcome in acute interstitial rejection. The incidence of B cell aggregates in vascular rejection and the effect of therapy with the monoclonal CD20 antibody rituximab on intrarenal B cells are currently unclear. METHODS: We analyzed the incidence of B cell clusters in patients with vascular rejection by immunohistochemistry and compared the influence of rituximab treatment plus conventional therapy with that of conventional immunosuppression alone on intrarenal B cells. Furthermore intrarenal expression of the B cell attracting chemokine BCA-1/CXCL13 and the lymphoid chemokine SLC/CCL21 were analyzed. RESULTS: Nine of 16 patients with vascular rejection displayed intrarenal B cell clusters strictly co-localizing with expression of the B cell attractant chemokine BCA-1/CXCL13. Addition of rituximab to conventional treatment lead to complete depletion of intrarenal B cells (98.3+/-136.4 CD20, 90.7+/-113.2 CD19 vs. 0+/-0 CD20, 0+/-0 CD19 B cells/hpf, P
M3 - SCORING: Zeitschriftenaufsatz
VL - 84
SP - 842
EP - 850
JO - TRANSPLANTATION
JF - TRANSPLANTATION
SN - 0041-1337
IS - 7
M1 - 7
ER -